What stands out
- Earnings significantly exceed cash generation
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- FinancialsAltman Z-Score 6.9: safe zone
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
10.25%Above 5Y avg (2.94%)
Annual Rate
CNY 2.00Paid annual
Payout Ratio
207.2%High
Payback Period
9.3 yr
Last Ex-Dividend
Jul 1, 2026
The reported statements, read against the company's own industry.
What stands out
- Earnings significantly exceed cash generation
Financials view
Market Capitalization
4.58BCNY687.13M · vs all stocks (USD)
Trailing P/E
16.16xRevenue (TTM)
1.51BCNY226.09M · vs all stocks (USD)
Profit Margin
18.81%Beta
0.1340xvs all stocks
52-Week Change
-43.60%vs all stocks
Market Capitalization
4.58BCNY687.13M · vs all stocks (USD)
Enterprise Value
3.73BCNY558.92M · vs all stocks (USD)
Trailing P/E
16.16xForward P/E
8.43xPrice to Sales (TTM)
3.04xPrice to Book (MRQ)
1.80xEnterprise to Revenue
2.47xEnterprise to EBITDA
5.56xGross Margin
82.96%Profit Margin
18.81%Operating Margin
39.95%Return on Assets (TTM)
8.64%Return on Equity (TTM)
13.64%Revenue (TTM)
1.51BCNY226.09M · vs all stocks (USD)
Revenue per Share (TTM)
6.42CNYUpdated Nov 19, 2026Quarterly Revenue Growth
-92.30%Gross Profit (TTM)
1.22BCNY183.18M · vs all stocks (USD)
EBITDA (TTM)
1.14BCNY171.72M · vs all stocks (USD)
Net Income (TTM)
283.50MCNY42.52M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-29.24%Operating Cash Flow (TTM)
-15.82MCNY-2.37M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-170.67MCNY-25.60M · vs all stocks (USD)
Trailing Annual Dividend Rate
2.00CNYUpdated Nov 19, 2026Trailing Annual Dividend Yield
10.25%vs all stocks
5-Year Average Dividend Yield
2.94%vs all stocks
Payout Ratio
207.23%Minority Interest (Equity)
1.49BCNYFY2025 · Dec 31, 2025Revenue
2.23BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
331.79MCNYFY2025 · Dec 31, 2025Gross Profit
1.90BCNYFY2025 · Dec 31, 2025Operating Income
1.19BCNY178.99M · vs all stocks (USD)
Pre-tax Income
1.21BCNYFY2025 · Dec 31, 2025Income Tax Expense
178.45MCNYFY2025 · Dec 31, 2025Net Income
1.03BCNYFY2025 · Dec 31, 2025EBIT
1.19BCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
1.30BCNYFY2025 · Dec 31, 2025Research & Development
91.10MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
337.62MCNYFY2025 · Dec 31, 2025Other Operating Expenses
46.01MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
24.06MCNYFY2025 · Dec 31, 2025EPS (Basic)
2.28CNYFY2025 · Dec 31, 2025EPS (Diluted)
2.28CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
234.69MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
234.69MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
1.03BCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
-493.47MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
1.08BCNYFY2025 · Dec 31, 2025Free Cash Flow
1.05BCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
2.00BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
1.03BCNYFY2025 · Dec 31, 2025Other Non-cash Items
3.80MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
64.61MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-20.34MCNYFY2025 · Dec 31, 2025Capital Expenditures
-23.48MCNYFY2025 · Dec 31, 2025Purchase of Investments
-3.34BCNYFY2025 · Dec 31, 2025Sale of Investments
3.12BCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-242.45MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-585.83MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-585.83MCNYFY2025 · Dec 31, 2025Shares Outstanding
234.33MSharesUpdated Nov 19, 2026Float Shares
156.98MSharesUpdated Nov 19, 2026% Held by Insiders
36.53%vs all stocks
% Held by Institutions
7.72%vs all stocks
Total Cash (MRQ)
1.94BCNY291.50M · vs all stocks (USD)
Total Cash per Share (MRQ)
8.29CNYUpdated Nov 19, 2026Total Debt (MRQ)
0.00CNYvs all stocks (USD)
Total Debt to Equity (MRQ)
0.00xCurrent Ratio (MRQ)
13.03xBook Value per Share (MRQ)
10.88CNYUpdated Nov 19, 2026Total Assets
5.00BCNY749.68M · vs all stocks (USD)
Total Current Assets
3.63BCNYFY2025 · Dec 31, 2025Total Liabilities
647.45MCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.37BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
96.12MCNYFY2025 · Dec 31, 2025Total Current Liabilities
551.33MCNYFY2025 · Dec 31, 2025Cash
2.00BCNYFY2025 · Dec 31, 2025Cash Equivalents
18.23MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
2.01BCNYFY2025 · Dec 31, 2025Other Short-term Investments
1.25BCNYFY2025 · Dec 31, 2025Accounts Receivable
67.34MCNYFY2025 · Dec 31, 2025Inventory
78.41MCNYFY2025 · Dec 31, 2025Accounts Payable
36.87MCNYFY2025 · Dec 31, 2025Other Current Liabilities
16.66MCNYFY2025 · Dec 31, 2025Common Stock (Book)
234.33MCNYFY2025 · Dec 31, 2025Retained Earnings
2.44BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
4.35BCNY652.57M · vs all stocks (USD)
52-Week Low
18.41CNYUpdated Nov 19, 202652-Week High
34.95CNYUpdated Nov 19, 202652-Week Change
-43.60%vs all stocks
Beta
0.1340xvs all stocks
50-Day MA
23.05CNYUpdated Nov 19, 2026200-Day MA
27.11CNYUpdated Nov 19, 2026Avg 10-Day Volume
2.94MSharesUpdated Nov 19, 2026Avg 30-Day Volume
2.91MSharesUpdated Nov 19, 2026Diluted EPS (TTM)
1.21CNYUpdated Nov 19, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Earnings significantly exceed cash generationSignificant
Net Income (USD, TTM): 42,522,251.394Operating Cash Flow (USD, TTM): -2,372,549.17
Financial Health
Altman Z-Score 6.9: safe zoneNotable
Altman Z-Score: 6.90
High structural barrier to entryNotable
Barrier to Entry: 0.92
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Yabao Pharmaceutical Group Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Heilongjiang ZBD Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Zhejiang Sunflower Great Health Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Guizhou Sanli Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
SWS Hemodialysis Care Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Luoxin Pharmaceuticals Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Fuan Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Teyi Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Hunan Fangsheng Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Hangzhou Bio-Sincerity Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow